Could a common antidepressant supercharge lung cancer treatment?

NCT ID NCT06554613

Recruiting now Disease control Sponsor: Second Affiliated Hospital of Nanchang University Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This phase 2 trial is testing whether adding the antidepressant olanzapine to standard immunotherapy (nivolumab) helps people with advanced EGFR-negative non-small cell lung cancer live longer. About 156 participants will receive either the combination or immunotherapy alone for 6-8 weeks. Researchers will track overall survival and side effects to see if the combination is more effective.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Olanzapine (an antidepressant) combined with nivolumab (an immunotherapy drug)
What this could lead to: If it works, this could point toward a more effective first-line treatment for advanced lung cancer by boosting the immune system's response.
What could go wrong: This is a small, early-phase trial, so results may not be conclusive. Olanzapine can cause side effects like drowsiness and weight gain, and the combination may not improve outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NON-SMALL CELL LUNG CANCER

Contacts and locations

Locations

The Second Affiliated Hospital of Nanchang University
RECRUITING

Nanchang, Jiangxi, 330006, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.